Extractables and Leachables for Pharmaceuticals and Medical Devices
November 27, 2012
By:
Allen Kesselring, Ph.D.
,
EAG Life Sciences
Extractables and Leachable (E&L) studies challenge our industry due to their late stage occurrence and investigational nature. This white paper defines Extractables and Leachables and outlines an E&L study plan that is both scientifically relevant and compliant within GXP regulatory systems.
|
Elemental Impurities: Navigating the Proposed Regulations of USP <232> and <233>
November 1, 2012
By:
EAG Life Sciences
The implementation of the proposed chapters USP chapters on elemental impurities, <232> and <233> is best suited to the use of closed vessel digestion and analysis by an ICP analytical technique. This paper addresses the challenges involved, as well as appropriate methods, procedures, and limits associated with this analysis.
|
Robust Analytical Methods for Genotoxic Impurities
September 25, 2012
By:
Lloyd Currin
,
Allen Kesselring, Ph.D.
,
EAG Life Sciences
Genotoxic Impurities and Potential Genotoxic Impurities (GIs, PGIs) pose analytical method development and validation challenges for pharmaceutical development. This white paper illustrates overcoming specificity and low limits of detection difficulties for quantitative analysis of Genotoxic Impurities and Potential Genotoxic Impurities for methyl, ethyl and isopropyl camphor sulfonate esters in a drug substance.
|
Extractables and Leachables for Pharmaceuticals and Medical Devices
July 31, 2012
By:
Allen Kesselring, Ph.D.
,
EAG Life Sciences
Extractables and Leachables (E&L) studies challenge our industry due to their late stage occurrence and investigational nature. This white paper defines Extractables and Leachables and outlines an E&L study plan that is both scientifically relevant and compliant within GXP regulatory systems.
|
Robust Analytical Methods for Genotoxic Impurities
June 26, 2012
By:
Lloyd Currin
,
Eden Tesfu, Ph.D.
,
EAG Life Sciences
The reactive nature of genotoxic impurities and potential genotoxic impurities poses unique analytical method development and validation challenges. This case study illustrates a difficult development and validation for quantitative analysis of genotoxic impurities and potential genotoxic impurities for methyl, ethyl and isopropyl camphor sulfonate esters in a drug substance.
|
|